-
Longbio Pharma Secures RMB 100 Million in Series B2 Financing to Advance Clinical Programs
•
Longbio Pharma, a biopharmaceutical company specializing in biomacromolecule drug development and based in Shanghai, China, has reportedly secured nearly RMB 100 million in a Series B2 financing round. The round was led by Qiming Venture Partners, with the funds earmarked to accelerate the clinical trials of its core programs in…
-
Innovent Biologics’ Altruist Biologics Partners with Longbio Pharma in RMB 500 Million Deal
•
Altruist Biologics, the Contract Development and Manufacturing Organization (CDMO) unit of China-based Innovent Biologics, Inc. (HKG: 1801), has entered into a partnership with compatriot firm Longbio Pharma. The RMB 500 million (USD 70 million) deal will leverage Altruist’s NDA filing experience, world-class quality system, and continuous stable commercial manufacturing capacities to…
-
LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development
•
LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi in a Series A+ financing round led by existing investors. The funds will be used to accelerate a Phase I clinical study and pre-clinical research, expand the product pipeline, and enhance the technology platform. Company…
